Investors Overview

Company Name: Protein Sciences Corporation

Founded: 1983

Corporate Headquarters:
1000 Research Parkway, Meriden CT 06450 USA
Executive Offices, Pilot Plant cGMP Manufacturing, Quality Assurance, Research Antigens, Cell Culture

Other Locations:
875 Research Parkway, Meriden CT 06450 USA
Business Development, Finance, Quality Control, Regulatory Affairs, Pilot Plant cGMP Manufacturing, Product Realization Laboratory, Clinical Affairs

401 North Middletown Road, Pearl River NY 10965 USA
Large scale cGMP Manufacturing

Funding Sources:


Institutional Investors

  • Mertiva AB (Sweden)
  • Johnson & Johnson
  • Pacific Rim Ventures (Japan)
  • Wyeth/Pfizer
Development Partners
  • Diamyd Therapeutics (Sweden)
  • UMN Pharma (Japan)
Government Contracts
  • Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA): HHS0100200900106C Advanced Development of Recombinant Influenza Virus Vaccines

Investor Relations Contact:

Daniel Adams
Executive Chairman and Global Head of Business Development
1-203-686-0800 x303

Shareholder Relations Contact:

Rachael Felberbaum
Director, Corporate Communications and Shareholder Relations
1-203-599-6064 x164

Financial Profile

We are a privately held company founded in 1983. We generate revenue through technology licenses, GeneXpress product development and manufacturing services and our research antigens business, and have been self financing since 2006. Our revenues have grown rapidly to over $31 million in 2012 and we have been increasingly profitable and cash flow positive since 2009.

Our lead product, Flublok influenza vaccine, was approved by the U.S. FDA in January 2013 for adults 18-49 years old. We anticipate FDA approval of Flublok for use in people 50 years of age and older in early 2014.

Request More Information